Edit |   |
---|---|
Antigenic Specificity | CD200, Human |
Clone | REA1067 |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG1 |
Format | Vio Bright V423 conjugate |
Size | 100 tests in 200 µL |
Concentration | 1:50 |
Applications | Flow cytometry |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | CD200 Antibody, anti-human, Vio® Bright V423, REAfinity™. Clone REA1067 recognizes the human CD200 antigen, also known as MRC, MOX1/2, or OX-2, a type 1 membrane glycoprotein, which contains two immunoglobulin domains. Studies of the related gene in mouse and rat suggest that CD200 may regulate myeloid cell activity and delivers an inhibitory signal for the macrophage lineage in diverse tissues. CD200 may serve as a cancer stem cell marker as co-expression with other reported stem cell markers was found on prostate, breast, brain, and colon cancers. In addition, CD200 expression was shown to be a prognostic factor in AML and multiple myeloma. | Additional information: Clone REA1067 displays negligible binding to Fc receptors. |
Immunogen | n/a |
Other Names | MOX1, Mox2, MRC, OX2, MOX1/2 |
Gene, Accession # | Gene ID: 4345 |
Catalog # | 130-128-194 |
Price | $500 |
Order / More Info | CD200, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
Product Specific References | Minas, K. et al. (2006) Is the CD200/CD200 receptor interaction more than just a myeloid cell inhibitory signal? Crit. Rev. Immunol. 26: 213-230. | Kawasaki, B. T. et al. (2007) Co-expression of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. Biochem. Biophys. Res. Commun. 364: 778-782. | Moreaux, J. et al. (2007) CD200 as a prognostic factor in acute myeloid leukemia. Blood 108: 4194-4197. | Tonks, A. et al. (2007) CD200 as a prognostic factor in acute myeloid leukemia. Leukemia 21: 566-568. |